Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2016

View Archived Issues

Novel S1P1 and S1P5 selective agonists identified for the treatment of autoimmune disease

Suven presents potent and selective H3R ligands with cognition-enhancing potential

DUOC-01 cells accelerate brain remyelination in vivo

Basilea Pharmaceutica patents MAPK inhibitors

F. Hoffmann-La Roche discloses HBsAg inhibitors

Chiesi develops compounds with mAChR antagonistic and beta2-adrenoceptor agonist activity

Merck Patent describes IRAK inhibitors

AbbVie reports SUV420H1 inhibitors

Early AR-101 immunotherapy is safe and effective in peanut-allergic preschool children

Researchers aim to find therapies for patients with hard-to-treat lymphomas

FDA gives favorable feedback to Corium's pre-IND application for Corplex memantine

FDA grants orphan drug designation to TG Therapeutics' TGR-1202

Ardelyx identifies promising gut-restricted TGR5 agonists

Insys Therapeutics reports positive results in phase III trial of buprenorphine sublingual spray

Abcellera Biologics completes antibody discovery partnership with Kodiak Sciences

Amgen receives FDA complete response letter for Parsabiv

Nymox Pharmaceutical announces positive results on fexapotide phase III trial

Mallinckrodt to sell its nuclear imaging business to IBA Molecular

Biothera expands collaboration with Merck & Co. for Keytruda combination study

FDA grants orphan drug designation to Scynexis' SCY-078 antifungal agent

FDA grants orphan drug designation to SFX-01 for the treatment of subarachnoid haemorrhage

Immix Biopharma completes stability testing for Imx-110

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...